These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 9918213)
1. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213 [TBL] [Abstract][Full Text] [Related]
2. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441 [TBL] [Abstract][Full Text] [Related]
3. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma. Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804 [TBL] [Abstract][Full Text] [Related]
4. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326 [TBL] [Abstract][Full Text] [Related]
5. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Safranek J; Pesta M; Holubec L; Kulda V; Dreslerova J; Vrzalova J; Topolcan O; Pesek M; Finek J; Treska V Anticancer Res; 2009 Jul; 29(7):2513-7. PubMed ID: 19596921 [TBL] [Abstract][Full Text] [Related]
6. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Iniesta P; Morán A; De Juan C; Gómez A; Hernando F; García-Aranda C; Frías C; Díaz-López A; Rodríguez-Jiménez FJ; Balibrea JL; Benito M Oncol Rep; 2007 Jan; 17(1):217-23. PubMed ID: 17143501 [TBL] [Abstract][Full Text] [Related]
7. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Hrabec E; Strek M; Nowak D; Hrabec Z Respir Med; 2001 Jan; 95(1):1-4. PubMed ID: 11207010 [TBL] [Abstract][Full Text] [Related]
8. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hayasaka A; Suzuki N; Fujimoto N; Iwama S; Fukuyama E; Kanda Y; Saisho H Hepatology; 1996 Nov; 24(5):1058-62. PubMed ID: 8903375 [TBL] [Abstract][Full Text] [Related]
9. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371 [TBL] [Abstract][Full Text] [Related]
10. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Endo K; Maehara Y; Baba H; Yamamoto M; Tomisaki S; Watanabe A; Kakeji Y; Sugimachi K Anticancer Res; 1997; 17(3C):2253-8. PubMed ID: 9216697 [TBL] [Abstract][Full Text] [Related]
11. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis. Hitchon CA; Danning CL; Illei GG; El-Gabalawy HS; Boumpas DT J Rheumatol; 2002 Jan; 29(1):107-17. PubMed ID: 11824946 [TBL] [Abstract][Full Text] [Related]
12. Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer. Li L; Mei TH; Zhou XD; Zhang XG Ai Zheng; 2009 Jan; 28(1):60-3. PubMed ID: 19448419 [TBL] [Abstract][Full Text] [Related]
13. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival. Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127 [TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue. Matsunaga Y; Koda M; Murawaki Y Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313 [TBL] [Abstract][Full Text] [Related]
15. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix]. Zhou CY; Yao JF; Chen XD Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097 [TBL] [Abstract][Full Text] [Related]
16. Expression of mRNA MMP-7 and mRNA TIMP-1 in non-small cell lung cancer. Safranek J; Holubec L; Topolcan O; Pesta M; Klecka J; Vodicka J; Finek J; Kormunda S; Pesek M Anticancer Res; 2007; 27(4C):2953-6. PubMed ID: 17695477 [TBL] [Abstract][Full Text] [Related]
17. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma]. Guo W; Chen G; Zhu C; Wang H Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):604-7. PubMed ID: 12487935 [TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Janowska-Wieczorek A; Marquez LA; Matsuzaki A; Hashmi HR; Larratt LM; Boshkov LM; Turner AR; Zhang MC; Edwards DR; Kossakowska AE Br J Haematol; 1999 May; 105(2):402-11. PubMed ID: 10233411 [TBL] [Abstract][Full Text] [Related]
19. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401 [TBL] [Abstract][Full Text] [Related]
20. [Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in joint tissues of rapidly destructive coxarthropathy (RDC), analyzed by immunohistochemical study]. Matsumoto F; Uzuki M; Kaneko C; Rikimaru A; Kokubun S; Sawai T Ryumachi; 1997 Oct; 37(5):688-95. PubMed ID: 9396371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]